Sarah Hein, co-founder and CEO of March Biosciences, joins the Houston Innovators Podcast to discuss how the company will use its series A funding. Photo via march.bio

When cancer originates in a patient, their body fights as hard as it can against the disease, but sometimes, the cancer wins the battle. However, one Houston cell therapy startup is working on an artillery of therapeutics to help arm patients' bodies to win the war.

Founded in 2022, March Biosciences is a cell therapy company born in part out of the Texas Medical Center's Accelerator for Cancer Therapeutics, where Sarah Hein served as inaugural entrepreneur in residence. In that role, she met her co-founders Max Mamonkin and Malcolm Brenner.

Now, leading the startup as CEO, Hein tells the Houston Innovators Podcast that with March's lead product, MB-105, an autologous CD5 CAR T cell therapy, the name of the game is to zero in on advancing this particular treatment to its phase II trial next year.

"Targeted therapies are targeted. Our target is expressed on these T-cell cancers, and there are a couple other cancers, like Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia," Hein says on the show. "Unfortunately, I don't think there's ever going to be a magic bullet that is going to hit a huge swath of these cancers. We're going to continue to chip away at these cancers by creating really elegantly engineered therapies against these different kinds of tumors.

"March, in general, is committed to this idea that we're going to continue to work on difficult tumors and different targets with our uniquely engineered targeting strategy against these diseases. As we expand into the next year, you'll see us speak on this a little more on how we're going to continue to work on new diseases that havent been addressed previously," she continues.

Hein explains how March Biosciences — named in part as a nod to one of Houston's best months weather wise — has benefitted from the support of the local life science community. Last year, March announced its partnership with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. Hein says over the past year, they've moved into CTMC and that's allowed them to accelerate their progress as a company.

"Houston has a unique sophistication in cell therapy. Where we've had biotech spinout, cell therapy has been one of our more successful verticals," she says. "We've had resources and knowledge here that were uniquely available for our drug category."

Earlier this month, March Biosciences announced an oversubscribed $28.4 million series A led by Mission BioCapital and 4BIO Capital and bringing the company's total funding secured to more than $51 million, including its prestigious CPRIT grant. Hein says this funding will go toward further developing March's therapeutics and team as it gears up for its phase II trial next year.

Ultimately, Hein explains on the show how passionate she is and her team is on continuing to develop treatments to fight cancer with their targeted approach.

"I never have to explain to people why we would go out and fight cancer. I think it's a self-evident hypothesis," she says. "But what I personally find is exciting in cancer therapies in general are these immune therapies, where you using the body's own immune system to seek out and destroy the cancer cells.

"What's really exciting about that is these are the same immune cells that fight cancer or pre-cancers for most of your life and usually what happens is the cancers figure out a way to mass themselves. With modern approaches, we can boost the immune system."

The Texas Medical Center's ACT program is making sure the most-promising cancer research makes it to its life-saving commercialization stage. Photo via tmc.edu

Houston program buoys promising cancer research with live-saving innovation

act-ing now

How do you bring promising cancer research to the masses? TMC Innovation's Accelerator for Cancer Therapeutics was established with that question in mind.

Funded by a $5 million grant from CPRIT, or the Cancer Prevention and Research Institute of Texas, in 2019 and in collaboration with the Gulf Coast Consortia and the University of Texas Medical Branch, the first cohort began their intensive work in 2021. The deadline to join the next cohort is October 13.

Since its inception, ACT has seen the forming of 19 companies — two of which have been awarded CPRIT seed grants, along with four in contention for one this year — as well as $92 million in dilutive funding and $10 million in non-dilutive funding.

“We’ve recruited investigators and companies from the breadth and width of the state of Texas, so all the way from Lubbock to Galveston from Dallas to the Rio Grande Valley,” Ahmed AlRawi, program manager, tells InnovationMap. “We've had an amazing set of investigators who have gone through the program — 56 teams to be precise.”

AlRawi says that the first pillar of the program is education. To that end, the cohort works with entrepreneurs in residence like Michael Torres. Best known as the co-founder of ReCode Therapeutics, Torres says that one of his greatest passions lies in translating science into medicines. ReCode is a genetic medicines company that is currently clinical-stage. It’s raised more than $300 million in the last two years, certainly something to which scientist-entrepreneurs earlier in their careers would aspire.

A longtime resident of Dallas, Torres moved his family to Houston last year, calling it “the place to be for cancer startups in Texas.”

Initially, says Torres, Houston wasn’t on his radar. But thanks to a call from ACT external advisor Dan Hargrove, Torres realized that the city might be a fit for him and his goals.

“I wanted to find a project that I could help support, sort of take my experience as a cofounder and help guide the next great startup within the ecosystem,” he says.

Torres and AlRawi agree that the biggest successes to come out of ACT so far include March Biosciences, a company from the first cohort, which is focused on developing CAR-T cell strategies to help combat hematological cancers; CPRIT fundee, OmniNano Pharmaceuticals, which uses patented nanotechnology to co-deliver a pair of therapeutical agents to solid tumors; and the latest, CrossBridge Bio.

Part of the most recent cohort, Torres has joined Drs. Kyoji Tsuchikama and Zhiqiang An as the last company’s CEO. To that end, he’s partnered with the world-class researchers out of UT Health Houston to build a next-generation antibody drug conjugate company that he believes will produce “better and safer and more effective drugs than what's currently on the market today.”

All the more reason that Torres he’s glad to have moved to Houston at what he calls “a really exciting time.” He’s thankful for the Texas Medical Center and the relationships it fosters. “We're all sort of aligning on creating a sustainable biotech ecosystem,” he says. And the next big cancer fighting company may well emerge from ACT.

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Houston immunotherapy company to use $13.5M grant to further develop cancer treatments

future of pharma

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas.

Launched in 2016, 7 Hills Pharma is working to develop drugs that can overcome the all-too-common problem of immunotherapy resistance. Thanks to the Nobel Prize-winning work of Jim Allison in the realm of immuno-oncology, the field was “very hot” at the time, says Marathi, particularly in Houston.

So what has 7 Hills developed? Oral small molecules that activate integrins — the receptors that allow cells to bind to one another — allowing for the cell-to-cell interactions that create a successful immune response to immune checkpoint inhibitors such as Yervoy. In other words, they have created capsules that increase the effectiveness of drugs that allow the body’s own immune response to fight cancers.

But that’s not all. Tests have shown that the same discovery, called alintegimod, can also augment the effectiveness of vaccines. The pill, which co-founder and co-inventor Peter Vanderslice calls “a beautiful way to amplify the vaccines,” can potentially be applied to anything from influenza to coronavirus.

Their greatest challenge, says Vanderslice, is the very fact that the technology is so novel.

“Most large pharmas are very risk averse,” he explains. “They only want to do ‘me-too’ kinds of drugs.”

7 Hills Pharma is the third company Marathi, both a PhD and an MBA, has helped to found based on technology he co-invented. Vanderslice is director of the molecular cardiology research laboratories at The Texas Heart Institute.

“It’s very much a homegrown company,” Marathi says.

And a small one, at least for now. Working out of JLabs@TMC, the full-time team is currently just Marathi and Siddhartha De, the senior director of development. Marathi convinced De to transplant himself and his family from India for the purpose of assisting 7 Hills with preparing its drugs for clinical readiness.

The CPRIT funds will allow 7 Hills Pharma to hire several long-time team members full-time and with benefits.

“The bringing of talent and bringing of technology to TMC and what was born at Texas Heart Institute is rather remarkable,” says Rob Bent, the company’s director of operations.

The next step for 7 Hills Pharma is a Phase Ib/IIa clinical trial in patients with treatment-resistant solid tumors. And the team just finalized the deck that will help raise another $10 million to $250 million in the company’s series A. And hopefully sooner rather than later, a new set of medical pilgrims will be thanking 7 Hill Pharma for its care.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston wearable biosensing company closes $13M pre-IPO round

fresh funding

Wellysis, a Seoul, South Korea-headquartered wearable biosensing company with its U.S. subsidiary based in Houston, has closed a $13.5 million pre-IPO funding round and plans to expand its Texas operations.

The round was led by Korea Investment Partners, Kyobo Life Insurance, Kyobo Securities, Kolon Investment and a co-general partner fund backed by SBI Investment and Samsung Securities, according to a news release.

Wellysis reports that the latest round brings its total capital raised to about $30 million. The company is working toward a Korea Securities Dealers Automated Quotations listing in Q4 2026 or Q1 2027.

Wellysis is known for its continuous ECG/EKG monitor with AI reporting. Its lightweight and waterproof S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge.

The company says that the funding will go toward commercializing the next generation of the S-Patch, known as the S-Patch MX, which will be able to capture more than 30 biometric signals, including ECG, temperature and body composition.

Wellysis also reports that it will use the funding to expand its Houston-based operations, specifically in its commercial, clinical and customer success teams.

Additionally, the company plans to accelerate the product development of two other biometric products:

  • CardioAI, an AI-powered diagnostic software platform designed to support clinical interpretation, workflow efficiency and scalable cardiac analysis
  • BioArmour, a non-medical biometric monitoring solution for the sports, public safety and defense sectors

“This pre-IPO round validates both our technology and our readiness to scale globally,” Young Juhn, CEO of Wellysis, said in the release. “With FDA-cleared solutions, expanding U.S. operations, and a strong AI roadmap, Wellysis is positioned to redefine how cardiac data is captured, interpreted, and acted upon across healthcare systems worldwide.”

Wellysis was founded in 2019 as a spinoff of Samsung. Its S-Patch runs off of a Samsung Smart Health Processor. The company's U.S. subsidiary, Wellysis USA Inc., was established in Houston in 2023 and was a resident of JLABS@TMC.

Elon Musk vows to launch solar-powered data centers in space

To Outer Space

Elon Musk vowed this week to upend another industry just as he did with cars and rockets — and once again he's taking on long odds.

The world's richest man said he wants to put as many as a million satellites into orbit to form vast, solar-powered data centers in space — a move to allow expanded use of artificial intelligence and chatbots without triggering blackouts and sending utility bills soaring.

To finance that effort, Musk combined SpaceX with his AI business on Monday, February 2, and plans a big initial public offering of the combined company.

“Space-based AI is obviously the only way to scale,” Musk wrote on SpaceX’s website, adding about his solar ambitions, “It’s always sunny in space!”

But scientists and industry experts say even Musk — who outsmarted Detroit to turn Tesla into the world’s most valuable automaker — faces formidable technical, financial and environmental obstacles.

Feeling the heat

Capturing the sun’s energy from space to run chatbots and other AI tools would ease pressure on power grids and cut demand for sprawling computing warehouses that are consuming farms and forests and vast amounts of water to cool.

But space presents its own set of problems.

Data centers generate enormous heat. Space seems to offer a solution because it is cold. But it is also a vacuum, trapping heat inside objects in the same way that a Thermos keeps coffee hot using double walls with no air between them.

“An uncooled computer chip in space would overheat and melt much faster than one on Earth,” said Josep Jornet, a computer and electrical engineering professor at Northeastern University.

One fix is to build giant radiator panels that glow in infrared light to push the heat “out into the dark void,” says Jornet, noting that the technology has worked on a small scale, including on the International Space Station. But for Musk's data centers, he says, it would require an array of “massive, fragile structures that have never been built before.”

Floating debris

Then there is space junk.

A single malfunctioning satellite breaking down or losing orbit could trigger a cascade of collisions, potentially disrupting emergency communications, weather forecasting and other services.

Musk noted in a recent regulatory filing that he has had only one “low-velocity debris generating event" in seven years running Starlink, his satellite communications network. Starlink has operated about 10,000 satellites — but that's a fraction of the million or so he now plans to put in space.

“We could reach a tipping point where the chance of collision is going to be too great," said University at Buffalo's John Crassidis, a former NASA engineer. “And these objects are going fast -- 17,500 miles per hour. There could be very violent collisions."

No repair crews

Even without collisions, satellites fail, chips degrade, parts break.

Special GPU graphics chips used by AI companies, for instance, can become damaged and need to be replaced.

“On Earth, what you would do is send someone down to the data center," said Baiju Bhatt, CEO of Aetherflux, a space-based solar energy company. "You replace the server, you replace the GPU, you’d do some surgery on that thing and you’d slide it back in.”

But no such repair crew exists in orbit, and those GPUs in space could get damaged due to their exposure to high-energy particles from the sun.

Bhatt says one workaround is to overprovision the satellite with extra chips to replace the ones that fail. But that’s an expensive proposition given they are likely to cost tens of thousands of dollars each, and current Starlink satellites only have a lifespan of about five years.

Competition — and leverage

Musk is not alone trying to solve these problems.

A company in Redmond, Washington, called Starcloud, launched a satellite in November carrying a single Nvidia-made AI computer chip to test out how it would fare in space. Google is exploring orbital data centers in a venture it calls Project Suncatcher. And Jeff Bezos’ Blue Origin announced plans in January for a constellation of more than 5,000 satellites to start launching late next year, though its focus has been more on communications than AI.

Still, Musk has an edge: He's got rockets.

Starcloud had to use one of his Falcon rockets to put its chip in space last year. Aetherflux plans to send a set of chips it calls a Galactic Brain to space on a SpaceX rocket later this year. And Google may also need to turn to Musk to get its first two planned prototype satellites off the ground by early next year.

Pierre Lionnet, a research director at the trade association Eurospace, says Musk routinely charges rivals far more than he charges himself —- as much as $20,000 per kilo of payload versus $2,000 internally.

He said Musk’s announcements this week signal that he plans to use that advantage to win this new space race.

“When he says we are going to put these data centers in space, it’s a way of telling the others we will keep these low launch costs for myself,” said Lionnet. “It’s a kind of powerplay.”

Johnson Space Center and UT partner to expand research, workforce development

onward and upward

NASA’s Johnson Space Center in Houston has forged a partnership with the University of Texas System to expand collaboration on research, workforce development and education that supports space exploration and national security.

“It’s an exciting time for the UT System and NASA to come together in new ways because Texas is at the epicenter of America’s space future. It’s an area where America is dominant, and we are committed as a university system to maintaining and growing that dominance,” Dr. John Zerwas, chancellor of the UT System, said in a news release.

Vanessa Wyche, director of Johnson Space Center, added that the partnership with the UT System “will enable us to meet our nation’s exploration goals and advance the future of space exploration.”

The news release noted that UT Health Houston and the UT Medical Branch in Galveston already collaborate with NASA. The UT Medical Branch’s aerospace medicine residency program and UT Health Houston’s space medicine program train NASA astronauts.

“We’re living through a unique moment where aerospace innovation, national security, economic transformation, and scientific discovery are converging like never before in Texas," Zerwas said. “UT institutions are uniquely positioned to partner with NASA in building a stronger and safer Texas.”

Zerwas became chancellor of the UT System in 2025. He joined the system in 2019 as executive vice chancellor for health affairs. Zerwas represented northwestern Ford Bend County in the Texas House from 2007 to 2019.

In 1996, he co-founded a Houston-area medical practice that became part of US Anesthesia Partners in 2012. He remained active in the practice until joining the UT System. Zerwas was chief medical officer of the Memorial Hermann Hospital System from 2003 to 2008 and was its chief physician integration officer until 2009.

Zerwas, a 1973 graduate of the Houston area’s Bellaire High School, is an alumnus of the University of Houston and Baylor College of Medicine.